Trial · NCT07893392
Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases
NCT07893392, Phase 2, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases. Trials, record NCT07893392. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893392
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases
- NCT number
- NCT07893392
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 73 participants, estimated
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Conditions
- Biliary Tract Cancer (BTC), Surgery, Radiotherapy
- Interventions
- Primary Tumor Resection and Selective Lymph Node Dissection, Postoperative Radiotherapy, Capecitabine or S-1
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Median Overall Survival | 24 months | Median Overall Survival (mOS) is defined as the median of Overall Survival (OS). OS is defined as the time from the date of surgery to death from any cause |
| Secondary | Median Progression-free Survival | 24 months | Median Progression-free Survival (mPFS) is defined as the median of Progression-free Survival (PFS). PFS is defined as the time from the date of surgery until tumor progression or death from any cause. |
| Secondary | R0/R1 resection rate | At the completion of surgery | R0/R1 Resection Rate is defined as the percentage of patients who achieve R0 or R1 resection among all patients undergoing surgery |
| Secondary | Completion Rate of Treatment Protocol | Up to 6 months after surgery | Completion Rate of the Surgery Plus Radiotherapy Treatment Protocol is defined as the percentage of patients who complete both planned surgery and postoperative radiotherapy according to the study protocol. |
| Secondary | Objective Response Rate (ORR) in Patients Undergoing R2 Resection | Assessment in 1 to 3 months after radiotherapy | Objective Response Rate (ORR) After Postoperative Radiotherapy in Patients Undergoing R2 Resection is defined as the percentage of patients with R2 resection who achieve complete response (CR) or partial response (PR) as their best overall response within 3 months after completion of postoperative radiotherapy, according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) and RECIST 1.1. |
| Secondary | Incidence of Grade ≥3 Adverse Events Following Postoperative Radiotherapy | 24 months | Adverse events are assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The outcome is defined as the proportion of patients who experience grade ≥3 adverse events following postoperative radiotherapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893392
GET https://conductscience.org/api/trials/v1/NCT07893392/registered